Vanguard Asset Management
APGE icon

Vanguard Asset Management’s Apogee Therapeutics APGE Stock Holding History

Vanguard Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.86M Buy
29,045
+3,389
+13% +$305K ﹤0.01% 1192
2026
Q1 		$2.16M Buy
+25,656
New +$1.86M ﹤0.01% 1422

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Asset Management's APGE Position: Q2 2026 in Review

Vanguard Asset Management increased its Apogee Therapeutics (APGE) stake by 13% in Q2 2026, buying an estimated $305K and bringing the position to 29,045 shares worth $3.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1192.

Vanguard Asset Management first reported a position in APGE in Q1 2026 and has held it in 2 quarters since. 281 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Vanguard Asset Management held 29,045 shares of Apogee Therapeutics worth $3.86M as of Q2 2026.
  • Vanguard Asset Management bought 3,389 Apogee Therapeutics shares in Q2 2026, an estimated $305K.
  • Apogee Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1192 holding.
  • Vanguard Asset Management first reported a position in Apogee Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 281 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.